Skip to content
Find My Test

Grail Galleri Multi-Cancer Test from Superpower

Labbrary Test GradeUseful
Your Fit Score
Not calculated

Answer five questions to see how this panel matches your goals, budget, collection preferences, access, and support needs.

Calculate my fit

Labbrary's review, Fit Score, and basic comparison are free. The provider's panel, shipping, collection, clinician review, and other services are separate. About 2 minutes. No account required.

Screens a blood sample for cancer-associated DNA methylation signals and, when a signal is detected, predicts a possible tissue of origin. Positive results require diagnostic follow-up; negative results do not rule out cancer or replace routine screening.

Current price
$949
Sample
Blood
Turnaround
14 to 21 days
Access
At Home, Mail In, Membership, Order Online
Evidence & Key Facts
Source collectedLast source check September 8, 2026

Evidence basis. This named result reflects the sources and verification evidence listed on this page as of the date shown.

Best for

Cancer Screening

Standout strength

One blood draw screens for signals associated with more than 50 cancer types in total and can provide a conditional Cancer Signal Origin prediction.

Important watch-out

Galleri is intended for adults at elevated cancer risk, such as people age 50 and older. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment.

Grail Galleri Multi-Cancer Test from Superpower
Labbrary Test GradeUseful
Your Fit Score
Not calculated

Answer five questions to see how this panel matches your goals, budget, collection preferences, access, and support needs.

Calculate my fit

Labbrary's review, Fit Score, and basic comparison are free. The provider's panel, shipping, collection, clinician review, and other services are separate. About 2 minutes. No account required.

Screens a blood sample for cancer-associated DNA methylation signals and, when a signal is detected, predicts a possible tissue of origin. Positive results require diagnostic follow-up; negative results do not rule out cancer or replace routine screening.

Current price
$949
Sample
Blood
Turnaround
14 to 21 days
Access
At Home, Mail In, Membership, Order Online
Evidence & Key Facts
Source collectedLast source check September 8, 2026

Evidence basis. This named result reflects the sources and verification evidence listed on this page as of the date shown.

Best for

Cancer Screening

Standout strength

One blood draw screens for signals associated with more than 50 cancer types in total and can provide a conditional Cancer Signal Origin prediction.

Important watch-out

Galleri is intended for adults at elevated cancer risk, such as people age 50 and older. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment.

Labbrary+

The Test Grade. The Reason Behind It.

Potentially useful for the right buyer, with meaningful evidence, coverage, transparency, access, cost, terms, or privacy tradeoffs to review.

A lower grade does not mean a panel is a bad personal fit. Your Fit Score can be higher when its purpose, price, sample, access, or support matches what you need.

Explore the Full Methodology
Labbrary Test GradeUseful

Next step

Review the panel or ask your clinician

This panel requires a licensed healthcare provider. Review the official details, then ask your clinician whether it is appropriate and how to order it.

View Official Panel DetailsView Superpower profile

Scope, both directions

Inside the Panel. Beyond the Name.

Named measurements

  • Cancer Signal Detected / No Cancer Signal Detected result (national and New York/New Jersey versions)
  • Cancer Signal Origin (CSO) prediction (national and New York/New Jersey versions)
  • Pancreatic cancer signal (national and New York/New Jersey versions)
  • Ovarian cancer signal (national and New York/New Jersey versions)
  • Liver and bile duct cancer signal (national and New York/New Jersey versions)
  • Esophageal cancer signal (national and New York/New Jersey versions)
  • Lung cancer signal (national and New York/New Jersey versions)
  • More than 50 cancer types screened in total (national and New York/New Jersey versions)

Measured categories and focus areas

  • Cancer Screening

Important limits and omissions

  • A complete named cancer-by-stage sensitivity inventory and patient-level report ranges remain unconfirmed.
  • Clinical utility, routine-use outcome benefit and the complete diagnostic follow-up cost path remain unresolved.
  • Confirm applicable membership charges, taxes and diagnostic follow-up costs. Galleri is non-refundable; membership cancellation follows separate terms.
  • Product-specific GRAIL specimen retention, destruction and exact data exchange with Superpower are not established.

The full breakdown

Eight Dimensions.
One Named Result.

Open any row for the reasoning and evidence behind the named result.

The exact offer page states this panel is processed by a CAP-accredited laboratory operated by GRAIL and describes its assays as a laboratory-developed test validated under CLIA that uses sequencing and machine learning to analyze methylation patterns; not cleared or approved by the FDA. The page does not publish assay precision data, reference-interval validation, or per-biomarker performance figures.

The exact offer page describes this panel for adults seeking multi-cancer early detection screening; the page states a prescription is required. The page states the test requires a prescription. It does not publish clinical guidelines or eligibility criteria beyond the page description.

The exact offer page screens for signals associated with more than 50 types of cancer and predicts the cancer signal origin. It does not publish a per-cancer list, so the inventory is described at the category level rather than as named analytes.

The exact offer page states results are typically ready in about a week and land in the Superpower app, and that results are interpreted by clinicians in context rather than as a stand-alone diagnosis. The page does not publish sample reports or reference intervals.

The exact offer page identifies Superpower as the provider, states the panel is processed by a CAP-accredited laboratory operated by GRAIL, and gives its regulatory status (FDA-cleared assay or laboratory-developed test validated under CLIA). Corporate ownership, full terms of service, and lab credentials beyond the stated certification are not published on the page.

The exact offer page states the test is available in 25 states, requires a prescription, and uses a single blood draw with results typically in two to three weeks. State-by-state availability beyond the 25-state figure is not published.

The exact offer page lists the panel at $949, and Superpower requires a $349 annual membership in addition to the panel price. Refund and cancellation terms for the panel itself are not published on the page.

Superpower publishes a privacy policy covering the service, and the panel page notes results are delivered through the Superpower app. The page does not publish a panel-specific data-handling statement, so how this panel's samples and data are stored, shared, or deleted beyond the general policy is not documented.

What it asks of you

Sample and fulfillment journey

Order

Confirmed

Order through Superpower with a required prescription arranged through the order. Confirm elevated-risk eligibility, address coverage, membership charges and diagnostic follow-up costs.

Panel-specific source · Source dated September 8, 2026

Collect

Confirmed

A licensed phlebotomist collects one blood sample at home. No fasting is required.

Panel-specific source · Source dated September 8, 2026

Lab

Confirmed

GRAIL analyzes DNA methylation patterns in the blood sample for cancer-associated signals. A detected signal can include a prediction of its tissue of origin.

Panel-specific source · Source dated September 8, 2026

Report

Confirmed

Receive results typically two to three weeks after collection. A detected signal requires diagnostic follow-up, and a no-signal result does not replace routine screening. Superpower care-team support is non-clinical.

Panel-specific source · Source dated September 8, 2026

Under the hood

Follow the Evidence.

Every published claim should trace to a dated source. Missing evidence remains visible instead of being filled with assumptions.

Source 1Recorded for this record. Last source check September 8, 2026.View source
Source 2Recorded for this record. Last source check September 8, 2026.View source
Source 3Recorded for this record. Last source check September 8, 2026.View source
Source 4Recorded for this record. Last source check September 8, 2026.View source
Source 5Recorded for this record. Last source check September 8, 2026.View source

True total cost

The Price. Plus the Details.

Pricing for Grail Galleri Multi-Cancer Test
ItemCurrent disclosed priceNote
Panel$949Ask the ordering clinician or provider to confirm the complete cost.
HSA/FSA paymentNot confirmedHSA/FSA payment eligibility has not been confirmed from provider documentation.
Optional servicesNot confirmedClinician review, subscriptions, and retesting discounts are listed only when documented.

Price status. A current panel price has not been confirmed. Ask the ordering clinician or provider to confirm testing, collection, shipping, and consultation fees.

Your data

Your Data. Your Questions.

Privacy details are scored only when source documentation is available. Unconfirmed retention, deletion, research use, or marketing practices remain unconfirmed.

Reading the labels

What Has Been Checked?

Source collected

Evidence labels stay separate from the Test Grade. They show how much source support exists for the evaluation.

The balance

The Strengths. The Tradeoffs.

Strengths

  • One blood draw screens for signals associated with more than 50 cancer types in total and can provide a conditional Cancer Signal Origin prediction.
  • Positive and no-signal results come with clear screening limitations and diagnostic follow-up guidance.
  • At-home licensed phlebotomy, no fasting and a typical two-to-three-week result window make the collection workflow clear.

Watch-outs

  • Galleri is intended for adults at elevated cancer risk, such as people age 50 and older. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment.
  • A detected signal is not a diagnosis and requires diagnostic follow-up. A no-signal result does not rule out cancer. False positives and false negatives are possible; continue routine screening recommended for you.
  • The $949 test fee is separate from annual membership of $199 nationally or $399 in New York and New Jersey. Membership renews annually unless cancelled under its terms. Galleri is non-refundable. Confirm applicable charges and diagnostic follow-up costs before ordering.
  • Home collection covers 24 states plus Washington, D.C., with a separate New York and New Jersey version. Confirm address coverage and clinical eligibility.
  • Cancer-signal performance estimates do not by themselves establish a survival benefit. Results require clinical context.
  • GRAIL-specific sample retention, data exchange and individualized report uncertainty have not been confirmed.

Take it with you

The Test Truth Card

The key facts from this review in one compact card.

Keep deciding

Galleri Multi-Cancer Early Detection Test

Mito Health

Useful

Analyzes cell-free DNA methylation patterns for a cancer-associated signal. A detected signal includes a predicted site of origin to guide diagnostic follow-up.

Price
$949
Turnaround
Not confirmed
See Labbrary reviewView Exact Panel on Provider Site
Labbrary+

Galleri® Multi-Cancer Early Detection Test

Everlywell

Strong

Analyze cell-free DNA methylation patterns for cancer-associated signals using a blood sample collected at Quest. If a signal is detected, the report predicts its likely origin to help guide further evaluation.

Price
$949
Turnaround
28 days
See Labbrary reviewView Exact Panel on Provider Site
Labbrary+

The Galleri Test

Galleri

Useful

Prescription blood test that looks for cancer-associated DNA methylation signals across more than 50 cancer types. It complements routine screening and predicts an origin when a signal is detected to guide diagnostic follow-up; a negative result does not rule out cancer.

Price
$799
Turnaround
28 days
See Labbrary reviewView Official Panel Details
Labbrary+
Compare
Run a Pre-Buy AuditExplore All TestsFind My Best-Fit Tests

Verification History

September 8, 2026Recorded source date.Source collected

Affiliate disclosure. Some outbound links may earn Labbrary a commission. Affiliate relationships never influence a Test Grade.

LABBRARY / FREE NEWSLETTER

Keep Your
Curiosity Informed.

New tests. Meaningful updates. Smarter questions to ask before you buy. Get Labbrary's free newsletter in your inbox.

Free to join. No account needed. Privacy Policy